BioSpace News Archive

Sonex Health and the Institute of Advanced Ultrasound Guided Procedures have announced they are hosting the first annual Musculoskeletal Ultrasound Forum, bringing surgeons together to exchange ideas, engage in hands-on learning activities, and shape the future of MSK ultrasound in hand surgery.

SOHM, Inc. (OTC PINK: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, announces today that it has acquired, ABBIE, a world-class gene-editing platform which can deliver genetic payloads using non-viral vectors.

The Global Ultrasound Institute has announced the completion of the largest scale ultrasound training effort for medical providers ever conducted.

Alto Neuroscience Inc. today reported results from the post-traumatic stress disorder (PTSD) cohort in its Phase 2a study of ALTO-100, demonstrating clear evidence of efficacy and favorable safety in patients with PTSD.

Todos Medical, Ltd., an innovative healthcare solutions company, provided a corporate update to its stakeholders centered on the Company’s efforts to retool and focus primarily on addressing the Long COVID epidemic that is affecting over 15 million Americans, over 6% of the adult US population, according to the US Centers for Disease Control.

Crossject, a specialty pharma company developing needle-free auto-injectors for emergency situations, announces its financial results for the first six months of 2023, ending June 30.

DiscGenics, Inc. announced that Flagg Flanagan, Chief Executive Officer and Chairman of DiscGenics will present at the following conferences.

ABM Therapeutics is pleased to announce today that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for the investigation of ABM-1310 for the treatment of Glioblastoma (GBM) patients carrying BRAF V600E mutation, following the Orphan Drug Designation for ABM-1310 to treat malignant gliomas including GBM received in July.

Nexus Pharmaceuticals, LLC announced it has received U.S. Food and Drug Administration (FDA) approval for Fluorescein Injection, USP.

Prodec Global UK Ltd unveils today CORE ASX®, a new supplement designed to support human wellbeing and optimize athletic performance like never before.